HOPHF (Hemogenyx Pharmaceuticals) 3-1 Month Momentum %: N/A% (As of Sep. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOPHF Hemogenyx Pharmaceuticals PLC HOPHF
29 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals 3-1 Month Momentum %?

Hemogenyx Pharmaceuticals HOPHF 29 3-1 Month Momentum % is N/A% as of Sep. 08, 2026. GuruFocus rates HOPHF with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, Hemogenyx Pharmaceuticals ranks worse than 68.24% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-08), Hemogenyx Pharmaceuticals's 3-1 Month Momentum % is N/A%.

The industry rank for Hemogenyx Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

HOPHF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -3.91
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Hemogenyx Pharmaceuticals  (OTCPK:HOPHF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Hemogenyx Pharmaceuticals 3-1 Month Momentum % Related Terms

HOPHF vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's 3-1 Month Momentum % falls into.


HOPHF
29GF Score
Hemogenyx Pharmaceuticals PLC HOPHF
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals  (OTCPK:HOPHF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Hemogenyx Pharmaceuticals (HOPHF) has a 3-1 Month Momentum % of N/A% as of Sep. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Hemogenyx Pharmaceuticals and its competitors. According to the industry distribution chart, Hemogenyx Pharmaceuticals ranks #952 out of 1395 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Hemogenyx Pharmaceuticals' 3-1 Month Momentum % too high?
Hemogenyx Pharmaceuticals' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Hemogenyx Pharmaceuticals ranks #952 out of 1395 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hemogenyx Pharmaceuticals ranks #952 out of 1395 companies for 3-1 Month Momentum %. This places Hemogenyx Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Hemogenyx Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current 3-1 Month Momentum % is N/A% as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Other Exchanges HEMO:UK
Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
29GF Score

Get the complete analysis for HOPHF

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price